By Colin Kellaher

Regeneron Pharmaceuticals Inc. and Sanofi SA on Monday said a Phase 3 study of their blockbuster eczema drug Dupixent to treat moderate-to-severe atopic dermatitis in children ages 6 months to 5 years met its primary and all secondary endpoints.

The companies said Dupixent added to standard-of-care topical corticosteroids significantly reduced overall disease severity and improved skin clearance, itch and health-related quality of life measures at 16 weeks compared to topical corticosteroids alone.

Regeneron and Sanofi said Dupixent, which is already approved for patients 6 years and older with uncontrolled moderate-to-severe atopic dermatitis, is the first biologic medicine to show positive results in the inflammatory skin disease in the study's young population.

Regeneron, of Tarrytown, N.Y., created Dupixent and markets it jointly in the U.S. with France's Sanofi under a 2007 collaboration agreement. Sanofi markets the product internationally.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

August 30, 2021 06:52 ET (10:52 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Sanofi Charts.